Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 15 June 2006, Vol. 107, No. 12, pp. 4628-4635.
Prepublished online as a Blood First Edition Paper on February 23, 2006; DOI 10.1182/blood-2005-11-4370.


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2005-11-4370v1
107/12/4628    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rosenberg, P. S.
Right arrow Articles by Dale, D. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rosenberg, P. S.
Right arrow Articles by Dale, D. C.
Related Collections
Right arrow Neoplasia
Right arrow Phagocytes
Right arrow Chemokines, Cytokines, and Interleukins
Right arrow Clinical Trials and Observations
Right arrowRelated Article in Blood Online
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

CLINICAL TRIALS AND OBSERVATIONS

The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy

Philip S. Rosenberg, Blanche P. Alter, Audrey A. Bolyard, Mary Ann Bonilla, Laurence A. Boxer, Bonnie Cham, Carol Fier, Melvin Freedman, George Kannourakis, Sally Kinsey, Beate Schwinzer, Connie Zeidler, Karl Welte, David C. Dale, for the Severe Chronic Neutropenia International Registry

From the Biostatistics Branch and Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Rockville, MD; Department of Medicine, University of Washington, Seattle, WA; Department of Pediatric Hematology Oncology, St Joseph's Children's Hospital, Paterson, NJ; Department of Pediatrics, University of Michigan Medical Center, Ann Arbor, MI; CancerCare Manitoba, Winnipeg, MB, Canada; Amgen, Inc, Boulder, CO; Hospital for Sick Children, Toronto, ON, Canada; Ballarat Oncology and Haemotology Services, Wendouree, Australia; St James's University Hospital, Leeds, United Kingdom; and Kinderklinik, Medizinische Hochschule, Hannover, Germany.

In patients with severe congenital neutropenia (SCN), sepsis mortality is reduced by treatment with granulocyte colony-stimulating factor (G-CSF), but myelodsyplastic syndrome and acute myeloid leukemia (MDS/AML) have been reported. We studied 374 patients with SCN and 29 patients with Shwachman-Diamond syndrome (SDS) on long-term G-CSF enrolled in the Severe Chronic Neutropenia International Registry. In SCN, sepsis mortality was stable at 0.9% per year. The hazard of MDS/AML increased significantly over time, from 2.9% per year after 6 years to 8.0% per year after 12 years on G-CSF. After 10 years, the cumulative incidence was 8% for sepsis mortality and 21% for MDS/AML. A subgroup of SCN patients (29%) received more than the median dose of G-CSF (≥ 8 µg/kg/d), but achieved less than the median absolute neutrophil count (ANC) response (ANC < 2.188 x 109/L [2188/µL] at 6-18 months). In these less-responsive patients, the cumulative incidence of adverse events was highest: after 10 years, 40% developed MDS/AML and 14% died of sepsis, compared with 11% and 4%, respectively, of more responsive patients whose ANC was above the median on doses of G-CSF below the median. Risk of MDS/AML may be similar in SDS and SCN. In less-responsive SCN patients, early hematopoietic stem cell transplantation may be a rational option.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Article in Blood Online:

Reconsidering how we treat severe congenital neutropenia
Kevin Shannon
Blood 2006 107: 4575-4576. [Full Text] [PDF]



This article has been cited by other articles:


Home page
haematolHome page
K. Beel and P. Vandenberghe
G-CSF receptor (CSF3R) mutations in X-linked neutropenia evolving to acute myeloid leukemia or myelodysplasia
Haematologica, October 1, 2009; 94(10): 1449 - 1452.
[Abstract] [Full Text] [PDF]


Home page
Am J Clin PatholHome page
M. Czader and A. Orazi
Therapy-Related Myeloid Neoplasms
Am J Clin Pathol, September 1, 2009; 132(3): 410 - 425.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
B. P. Alter, N. Giri, S. A. Savage, and P. S. Rosenberg
Cancer in dyskeratosis congenita
Blood, June 25, 2009; 113(26): 6549 - 6557.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
R. Gurion, A. Gafter-Gvili, M. Paul, L. Vidal, I. Ben-Bassat, M. Yeshurun, O. Shpilberg, and P. Raanani
Hematopoietic growth factors in aplastic anemia patients treated with immunosuppressive therapy-systematic review and meta-analysis
Haematologica, May 1, 2009; 94(5): 712 - 719.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. A. Pulsipher, P. Chitphakdithai, J. P. Miller, B. R. Logan, R. J. King, J. D. Rizzo, S. F. Leitman, P. Anderlini, M. D. Haagenson, S. Kurian, et al.
Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program
Blood, April 9, 2009; 113(15): 3604 - 3611.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. Germeshausen, K. Welte, and M. Ballmaier
In vivo expansion of cells expressing acquired CSF3R mutations in patients with severe congenital neutropenia
Blood, January 15, 2009; 113(3): 668 - 670.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
K. Boztug, G. Appaswamy, A. Ashikov, A. A. Schaffer, U. Salzer, J. Diestelhorst, M. Germeshausen, G. Brandes, J. Lee-Gossler, F. Noyan, et al.
A Syndrome with Congenital Neutropenia and Mutations in G6PC3
N. Engl. J. Med., January 1, 2009; 360(1): 32 - 43.
[Abstract] [Full Text] [PDF]


Home page
ASH ANNUAL MEETING ABSTRACTSHome page
L. A. Boxer, A. A. Bolyard, P. E. Newburger, M. A. Bonilla, G. Kannourakis, Y. Dror, D. C. Link, B. P. Alter, P. S. Rosenberg, and D. C. Dale
Risk for Septic Death in Severe Congenital Neutropenia
Blood (ASH Annual Meeting Abstracts), November 16, 2008; 112(11): 3548 - 3548.
[Abstract]


Home page
JCOHome page
M. Jadersten, L. Malcovati, I. Dybedal, M. Giovanni Della Porta, R. Invernizzi, S. M. Montgomery, C. Pascutto, A. Porwit, M. Cazzola, and E. Hellstrom-Lindberg
Erythropoietin and Granulocyte-Colony Stimulating Factor Treatment Associated With Improved Survival in Myelodysplastic Syndrome
J. Clin. Oncol., July 20, 2008; 26(21): 3607 - 3613.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
B. W. Robinson, N.-K. V. Cheung, C. P. Kolaris, S. C. Jhanwar, J. K. Choi, N. Osheroff, and C. A. Felix
Prospective tracing of MLL-FRYL clone with low MEIS1 expression from emergence during neuroblastoma treatment to diagnosis of myelodysplastic syndrome
Blood, April 1, 2008; 111(7): 3802 - 3812.
[Abstract] [Full Text] [PDF]


Home page
EDUCATION AND PRACTICEHome page
J Townshend, J Clark, A Cant, P Carey, P Kumar, and D Campbell
Congenital neutropenia
Arch. Dis. Child. Ed. Pract., February 1, 2008; 93(1): 14 - 18.
[Full Text] [PDF]


Home page
BloodHome page
L. M. R. Choi, C. Guelcher, and M. F. Guerrera
Novel treatment for severe congenital neutropenia with pegfilgrastim
Blood, December 1, 2007; 110(12): 4134 - 4134.
[Full Text] [PDF]


Home page
BloodHome page
R. Badolato, M. Donini, G. Savoldi, and S. Dusi
Response: ELA2 genotype-phenotype correlation to be expected in patients with severe congenital neutropenia
Blood, October 1, 2007; 110(7): 2773 - 2774.
[Full Text] [PDF]


Home page
BloodHome page
D. C. Link, G. Kunter, Y. Kasai, Y. Zhao, T. Miner, M. D. McLellan, R. E. Ries, D. Kapur, R. Nagarajan, D. C. Dale, et al.
Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia
Blood, September 1, 2007; 110(5): 1648 - 1655.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. Donini, S. Fontana, G. Savoldi, W. Vermi, L. Tassone, F. Gentili, E. Zenaro, D. Ferrari, L. D. Notarangelo, F. Porta, et al.
G-CSF treatment of severe congenital neutropenia reverses neutropenia but does not correct the underlying functional deficiency of the neutrophil in defending against microorganisms
Blood, June 1, 2007; 109(11): 4716 - 4723.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
B. P. Alter and P. S. Rosenberg
Granulocyte colony-stimulating factor and severe aplastic anemia
Blood, May 15, 2007; 109(10): 4589 - 4589.
[Full Text] [PDF]


Home page
BloodHome page
E. G. Blanchard and S. J. Corey
Filgrastim therapy: a bone of contention
Blood, April 15, 2007; 109(8): 3125 - 3126.
[Full Text] [PDF]


Home page
BloodHome page
G. Socie, J.-Y. Mary, H. Schrezenmeier, J. Marsh, A. Bacigalupo, A. Locasciulli, M. Fuehrer, A. Bekassy, A. Tichelli, and J. Passweg
Granulocyte-stimulating factor and severe aplastic anemia: a survey by the European Group for Blood and Marrow Transplantation (EBMT)
Blood, April 1, 2007; 109(7): 2794 - 2796.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. S. Horwitz, Z. Duan, B. Korkmaz, H.-H. Lee, M. E. Mealiffe, and S. J. Salipante
Neutrophil elastase in cyclic and severe congenital neutropenia
Blood, March 1, 2007; 109(5): 1817 - 1824.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
I. P. Touw and M. Bontenbal
Granulocyte Colony-Stimulating Factor: Key (F)actor or Innocent Bystander in the Development of Secondary Myeloid Malignancy?
J Natl Cancer Inst, February 7, 2007; 99(3): 183 - 186.
[Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
D. Hershman, A. I. Neugut, J. S. Jacobson, J. Wang, W.-Y. Tsai, R. McBride, C. L. Bennett, and V. R. Grann
Acute Myeloid Leukemia or Myelodysplastic Syndrome Following Use of Granulocyte Colony-Stimulating Factors During Breast Cancer Adjuvant Chemotherapy
J Natl Cancer Inst, February 7, 2007; 99(3): 196 - 205.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
B. P. Alter
Diagnosis, Genetics, and Management of Inherited Bone Marrow Failure Syndromes
Hematology, January 1, 2007; 2007(1): 29 - 39.
[Abstract] [Full Text] [PDF]


Home page
ASH-SAPHome page
D. C. Link and T. Wun
Myeloid disorders
ASH Self-Assessment Program, January 1, 2007; 2007(1): 143 - 171.
[Full Text] [PDF]


Home page
BloodHome page
M. Germeshausen, M. Ballmaier, and K. Welte
Incidence of CSF3R mutations in severe congenital neutropenia and relevance for leukemogenesis: results of a long-term survey
Blood, January 1, 2007; 109(1): 93 - 99.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
G. Ferretti, P. Papaldo, F. Cognetti, D. C. Dale, P. S. Rosenberg, B. P. Alter, and K. Kaushansky
Lineage-specific hematopoietic growth factors.
N. Engl. J. Med., August 3, 2006; 355(5): 526 - 527.
[Full Text] [PDF]


Home page
ASH Education BookHome page
P. E. Newburger
Disorders of Neutrophil Number and Function
Hematology, January 1, 2006; 2006(1): 104 - 110.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020